Akari Therapeutics Plc - ADR
AKTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.25M
Close$
$5.29
47.9% downside
Current Fair Value
47.9% downsideOvervalued by 47.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.25 Million |
|---|---|
| Enterprise Value | $5.25 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-20800 |
| Beta | 1.39 |
| Outstanding Shares | 1,791,468 |
Return
| Return on Equity | -166.70% |
|---|---|
| Return on Assets | -80.26% |
| Return on Invested Capital | -128.09% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 1.02 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.17 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-1.04
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
December 4, 2026
EPS Estimate
$-2.09
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.09%▼ 529.00% |
|---|---|
| Total Invested | $307,250▼ 76.12% |
| Investors Holding | 6▼ 15.00% |
ESG Score
No data
About Akari Therapeutics Plc
CEO: David Solomon